Numerous studies have focused on defining the specific phenotype of AML-associated LSCs, particularly within the CD34+CD38− cell compartment [131,132,133] and exploring potential markers such as CD133 [134], CD123 [135], and CD33 [136]. This evidence concerns the gene CD34 and acute myeloid leukemia.